Monte Rosa Therapeutics GLUE
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 11th percentile, 5-year average 2.6x
Around its usual level · 54th percentile, 5-year average 2.0x
#2639 of 5329 stocks by PB (1 = cheapest)
Above its usual level · 71st percentile, 5-year average 22.3x
#4550 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.61 | – | 2.03 | 54% (pricier than usual) | #2639 of 5329 (1 = cheapest) |
| PE | -6.74 | -3.82 | 2.60 | 11% (cheaper than usual) | – |
| PS | 11.39 | 17.95 | 22.26 | 71% (pricier than usual) | #4550 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on GLUE.
Sign in to join the discussion.